5,789 Shares in Glaukos Co. (NYSE:GKOS) Purchased by Williamson Legacy Group LLC

Williamson Legacy Group LLC purchased a new position in Glaukos Co. (NYSE:GKOS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,789 shares of the medical instruments supplier’s stock, valued at approximately $868,000.

A number of other institutional investors and hedge funds have also made changes to their positions in GKOS. Mutual of America Capital Management LLC increased its position in shares of Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after acquiring an additional 89 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after acquiring an additional 100 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock valued at $2,204,000 after acquiring an additional 100 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Glaukos by 3.3% during the third quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock valued at $416,000 after acquiring an additional 103 shares in the last quarter. Finally, New York State Teachers Retirement System increased its position in shares of Glaukos by 0.4% during the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Up 1.3 %

Shares of Glaukos stock opened at $119.87 on Friday. The company’s fifty day simple moving average is $150.84 and its 200-day simple moving average is $139.31. The stock has a market capitalization of $6.61 billion, a PE ratio of -41.77 and a beta of 1.04. Glaukos Co. has a 1-year low of $83.90 and a 1-year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The business had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on GKOS shares. Needham & Company LLC raised their price target on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. Piper Sandler restated an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and raised their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Insider Activity

In other news, Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,744 shares of company stock worth $2,792,151 in the last three months. Company insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.